1054PD - A New Classification for Nasopharyngeal Carcinoma

Date 09 September 2017
Event ESMO 2017 Congress
Session Head and neck cancer, excluding thyroid
Topics Cancers in Adolescents and Young Adults (AYA)
Head and Neck Cancers
Staging procedures (clinical staging)
Basic Principles in the Management and Treatment (of cancer)
Presenter Hung Chun Cheng
Citation Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374
Authors H.C.S. Cheng1, C. Horng2
  • 1Radiation Oncology, Koo Foundation Sun Yat-Sen Cancer Center, 112 - Taipei/TW
  • 2Clinical Research, Koo Foundation Sun Yat-Sen Cancer Center, 112 - Taipei/TW



This study is to develop and validate a new classification for nasopharyngeal carcinoma (NPC).


Fifteen hundred and twenty-eight (1528) newly diagnosed NPC patients treated between 1995 and 2010 were included in this study. Seven hundred and one patients (n = 701) were treated with 3D conformal radiotherapy (3D-RT) and 827 patients were treated with IMRT. Cox proportional hazards model was used to select the significant split node to partition patients into the different risk group. Recursive partitioning analysis derived a new classification in patients treated with 3D-RT objectively. This new staging system was then validated in patients treated with IMRT.


The median follow-up interval was 84.6 months (ranging 2-175 months). According to the 7th AJCC staging system, the stage I patients showed a 5-year overall survival (OS) rate of 93.0%, stage II of 94.5%, stage III of 87.5%, stage IVA of 71.5%, stage IVB of 61.3%, and stage IVC of 5.8% (p 


We propose a new staging system for NPC, which distributes more patients in the early stage.Table:

1054PD Patient Distribution According to Chinese 2008 and the 7th AJCC staging systems

StageChinese 2008 staging2010 AJCC stagingCurrent proposal
Stage I2.3%2.3%42.9%
Stage II11.0%23.7%21.9%
Stage III39.4%49.1%30.0%
Stage IV47.3%24.9%5.2%

Clinical trial identification

Not applicable

Legal entity responsible for the study



Koo Foundation Sun Yat-Sen Cancer Center


All authors have declared no conflicts of interest.